Vinva Investment Management Ltd Has $1.82 Million Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Vinva Investment Management Ltd reduced its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 65.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 13,291 shares of the company's stock after selling 25,249 shares during the quarter. Vinva Investment Management Ltd's holdings in Neurocrine Biosciences were worth $1,822,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Raymond James Financial Inc. bought a new stake in shares of Neurocrine Biosciences in the fourth quarter valued at about $115,193,000. Thrivent Financial for Lutherans lifted its stake in Neurocrine Biosciences by 2,759.4% in the 4th quarter. Thrivent Financial for Lutherans now owns 737,772 shares of the company's stock valued at $100,705,000 after acquiring an additional 711,970 shares in the last quarter. State Street Corp boosted its position in Neurocrine Biosciences by 11.7% during the 3rd quarter. State Street Corp now owns 5,148,293 shares of the company's stock worth $593,186,000 after acquiring an additional 539,936 shares during the last quarter. Jennison Associates LLC grew its stake in shares of Neurocrine Biosciences by 145.1% during the 4th quarter. Jennison Associates LLC now owns 820,694 shares of the company's stock worth $112,025,000 after acquiring an additional 485,894 shares in the last quarter. Finally, Impax Asset Management Group plc raised its holdings in shares of Neurocrine Biosciences by 207.8% in the fourth quarter. Impax Asset Management Group plc now owns 261,599 shares of the company's stock valued at $35,708,000 after purchasing an additional 176,599 shares during the last quarter. 92.59% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Insider Activity at Neurocrine Biosciences

In other Neurocrine Biosciences news, Director Kevin Charles Gorman sold 2,707 shares of the business's stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $152.92, for a total transaction of $413,954.44. Following the completion of the transaction, the director now directly owns 517,030 shares in the company, valued at $79,064,227.60. The trade was a 0.52 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Matt Abernethy sold 2,558 shares of the firm's stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $116.86, for a total value of $298,927.88. Following the completion of the sale, the chief financial officer now directly owns 34,775 shares in the company, valued at approximately $4,063,806.50. This represents a 6.85 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 233,178 shares of company stock valued at $33,906,594 over the last quarter. 4.30% of the stock is owned by corporate insiders.

Neurocrine Biosciences Stock Performance

Shares of NASDAQ NBIX traded up $0.58 during trading hours on Tuesday, reaching $116.18. 1,311,567 shares of the stock were exchanged, compared to its average volume of 958,764. The stock's fifty day simple moving average is $126.35 and its 200 day simple moving average is $125.13. The firm has a market capitalization of $11.58 billion, a price-to-earnings ratio of 35.31, a P/E/G ratio of 0.77 and a beta of 0.35. Neurocrine Biosciences, Inc. has a 52 week low of $105.18 and a 52 week high of $157.98.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last announced its earnings results on Thursday, February 6th. The company reported $1.00 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.62 by ($0.62). Neurocrine Biosciences had a return on equity of 13.38% and a net margin of 14.49%. Research analysts predict that Neurocrine Biosciences, Inc. will post 4.28 EPS for the current fiscal year.

Neurocrine Biosciences declared that its board has approved a share repurchase program on Friday, February 21st that authorizes the company to repurchase $500.00 million in shares. This repurchase authorization authorizes the company to reacquire up to 4.2% of its shares through open market purchases. Shares repurchase programs are usually a sign that the company's management believes its shares are undervalued.

Analysts Set New Price Targets

Several research analysts recently commented on the stock. UBS Group increased their target price on shares of Neurocrine Biosciences from $162.00 to $176.00 and gave the stock a "buy" rating in a report on Thursday, January 30th. Bank of America decreased their price objective on Neurocrine Biosciences from $184.00 to $179.00 and set a "buy" rating for the company in a report on Friday, February 7th. StockNews.com lowered Neurocrine Biosciences from a "strong-buy" rating to a "buy" rating in a report on Thursday, March 20th. Piper Sandler restated an "overweight" rating and issued a $160.00 price target on shares of Neurocrine Biosciences in a research note on Monday, December 23rd. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Neurocrine Biosciences in a research note on Friday, February 7th. Five analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Neurocrine Biosciences presently has a consensus rating of "Moderate Buy" and a consensus price target of $165.24.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.